Given the plethora of primary resistance literature, our report focuses on secondary resistance and reviews new treatment paradigms that combine optimized HER2-targeted therapies to improve outcomes for HER2-positive invasive breast cancer patients. The gene discussed is ERBB2; the disease is invasive breast carcinoma.